![Anish Tripathi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Anish Tripathi is the Chairman and founder of Epigeneres Biotech Pvt Ltd, which was founded in 2012.
Aktive Positionen von Anish Tripathi
Unternehmen | Position | Beginn |
---|---|---|
Epigeneres Biotech Pvt Ltd.
![]() Epigeneres Biotech Pvt Ltd. Pharmaceuticals: MajorHealth Technology Epigeneres Biotech Pvt Ltd. is an Indian company that focuses on detecting and treating cancer early. The company is based in Mumbai, India and was founded in 2012 by Anish Tripathi. In addition to their cancer detection technology, they also have a nutraceuticals business that specializes in molecular diagnostics and nutraceutical management for overall health and well-being. The company has developed a breakthrough technology based on the assumption that very small embryonic-like stem cells (VSELs) undergo epigenetic changes and get transformed into cancer stem cells (CSCs). The company's HRC test has the potential to detect cancer at stage zero, which significantly improves the cost, time, and chances of survival. | Gründer | 25.04.2012 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Epigeneres Biotech Pvt Ltd.
![]() Epigeneres Biotech Pvt Ltd. Pharmaceuticals: MajorHealth Technology Epigeneres Biotech Pvt Ltd. is an Indian company that focuses on detecting and treating cancer early. The company is based in Mumbai, India and was founded in 2012 by Anish Tripathi. In addition to their cancer detection technology, they also have a nutraceuticals business that specializes in molecular diagnostics and nutraceutical management for overall health and well-being. The company has developed a breakthrough technology based on the assumption that very small embryonic-like stem cells (VSELs) undergo epigenetic changes and get transformed into cancer stem cells (CSCs). The company's HRC test has the potential to detect cancer at stage zero, which significantly improves the cost, time, and chances of survival. | Health Technology |